RCUS: רווח נקי למניה (EPS TTM) Arcus Bio

Scaling the immuno-oncology portfolio with the support of a pharma behemoth defines the potential of Arcus Biosciences, Inc. (RCUS), as confirmed by the 12-month net income per share trend shown on GURU.Markets, where the -3.63 level reflects the current value. Top scientists and R&D budgets ensure stability, while drug development follows scientific cycles, remaining independent of global GDP fluctuations.
פילוחי נתונים אנליטיים מרוכזים עבור Arcus Corp (RCUS)

Long-term partnerships of Arcus Biosciences, Inc. (RCUS) in immuno-oncology create inertial capital inflows, making the analysis of per-share earnings critical for evaluating the investment efficiency of future blockbusters. By examining the change in earnings per share over the last 12 months, an investor sees the net financial result distributed per share, allowing for an objective assessment of the business's fundamental value and the stability of market quotes.